Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurotec versus gabapentin for sensory symptoms in diabetic neuropathy
IRCT20130812014333N79Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Nov 2017
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of Neurotec and gabapentin in diabetic neuropathy (2 arms), sponsored by Kermanshah University of Medical Sciences. Primary endpoint: Severity of sensory symptoms. Started Nov 2017; status: completed.
02
Drugs
Neurotecgabapentin
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on IRCT20130812014333N79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130812014333N79.